Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immtech: Pafuramidine Trial Gets Fast-Track Status In China (China)

This article was originally published in PharmAsia News

Executive Summary

China's State Food and Drug Administration has granted Immtech Pharmaceuticals' application for fast-track status for conducting a Phase III clinical trial involving pafuramidine. Pafuramidine is the company's oral drug candidate for the treatment of Pneumocystis pneumonia, a fungal infection in the lungs that can cause potentially life-threatening pneumonia in patients with HIV and other immune-related diseases. (Click here for more - May Require Paid Subscription
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065678

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel